Targeted immunotherapy with the human anti-CD38 antibody daratumumab has recently emerged as a promising strategy for the treatment of multidrug resistant patients with multiple myeloma (MM). In experimental in vitro and in vivo settings, and in recently completed clinical trials, daratumumab
No takes yet. Share an insight, caveat, or question.
Haart et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: